VNDA Vanda Pharmaceuticals (VNDA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001347178
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
96
13F, latest reported quarter
Vanda Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Vanda Pharmaceuticals Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Mar 5, 2024.
- The trade is 11.2% of the 377,450 shares held after it.
- 5 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & General Counsel Williams Timothy sold about $350.9K of VNDA on Mar 2, 2026, the largest insider sale at the company since 2022; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (1 buy, 13 sales), the last on Feb 21, 2025.
- The trade is 10.3% of the 411,380 shares held after it.
- 5 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, CFO & Treasurer Moran Kevin Patrick sold about $351.0K of VNDA on Mar 2, 2026, the largest insider sale at the company since 2022; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 5, 2024.
- The trade is 9.2% of the 333,469 shares held after it.
- 5 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Marketing Officer Wijkstrom Joakim sold about $254.7K of VNDA on Mar 2, 2026, the largest insider sale at the company since 2022; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.Context
- 24 earlier Form 4 trades (code P or S) here by this insider (14 buys, 10 sales), the last on Aug 7, 2025.
- -7.9% median (-4.3% mean) 90-day return after 10 previous buys.
- The trade is 5.8% of the 2,704,496 shares held after it.
- 5 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Polymeropoulos Mihael Hristos sold about $1.3M of VNDA on Mar 2, 2026, the largest insider sale at the company on our record; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 5, 2024.
- The trade is 8.6% of the 494,197 shares held after it.
- 5 other insiders sold within 30 days.
- 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Business Development Birznieks Gunther sold about $350.9K of VNDA on Mar 2, 2026, the largest insider sale at the company since 2022; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.77 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
96 funds bought in last quarter
more than 66% of Pharma & Biotech
Revenue
+8.7% year over year
more than 58% of Pharma & Biotech
Margin
-102.0% net margin
below 58% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
16.7% of the float short (float per yahoo 2026-10-26) · 6.5 days to cover · settled 2026-09-30
more than 80% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch VNDA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-27.3%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VNDA: institutional holders (13F)
13F holdings, latest reported quarter
7,653,737 sh
$46.8M
3,516,405 sh
$21.5M
3,497,695 sh
$21.4M
3,441,361 sh
$21.1M
2,524,040 sh
$15.4M
Congress trades in VNDA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
VNDA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
VNDA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$220.6K position · as of 2026-06-30
0.7%
Horizon Kinetics Medical ETF
$138.6K position · as of 2026-06-30
0.7%
NVIT Small Cap Value Fund
$717.0K position · as of 2026-06-30
0.3%
Invesco NASDAQ Future Gen 200 ETF
$55.6K position · as of 2026-05-31
0.3%
GMO U.S. Small Cap Value Fund
$130.1K position · as of 2026-05-31
0.3%
Federated Hermes MDT Small Cap Core Fund
$5.5M position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
55 registered trials, 16 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
7
Phase 1
1 active
18
Phase 2
3 active
24
Phase 3
9 active
1
Phase 4
1 active
3
Not applicable
1 active
2
Multi-phase
1 active
What changed recently
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
2026-10-20 · Completion moved 2025-12 → 2026-03-30
Phase 3
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
2026-10-20 · Recruiting → Completed
Phase 3
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (
2026-10-10 · Completion moved 2026-09 → 2026-09-04
Phase 3
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (
2026-10-10 · Active Not Recruiting → Completed
Phase 3
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
2026-10-01 · Completion moved 2026-03-31 → 2028-12-31
Phase 4
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Dr. Mihael H. Polymeropoulos
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.9M
$7.6M
$1.4M
-33%
+20%
2024
$3.9M
$4.3M
$1.3M
-64%
-9%
2023
$3.7M
$1.8M
$1.4M
-68%
-8%
2022
$4.3M
$859.6K
$1.5M
-44%
-11%
2021
$6.2M
$5.6M
$2.0M
+19%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 96 funds added last quarter. Each figure is a federal filing, dated the day it went public.
VNDA financials
Revenue growth
+8.7%
XBRL, annual
Net margin
-102.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$215.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM VNDA
| FY Dec 2025 | $216.1M |
| FY Dec 2024 | $198.8M |
| FY Dec 2023 | $192.6M |
| FY Dec 2022 | $254.4M |
| FY Dec 2021 | $268.7M |
| Jun 2026 | $50.5M |
| Mar 2026 | $51.7M |
| Dec 2025 | $57.2M |
| Sep 2025 | $56.3M |
| Jun 2025 | $52.6M |
| Mar 2025 | $50.0M |
| Dec 2024 | $53.2M |
| Sep 2024 | $47.7M |
At each fiscal year end
Single quarter
Net margin, TTM
-127.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM VNDA
| FY Dec 2025 | -102.0% |
| FY Dec 2024 | -9.5% |
| FY Dec 2023 | +1.3% |
| FY Dec 2022 | +2.5% |
| FY Dec 2021 | +12.4% |
| Jun 2026 | -123.7% |
| Mar 2026 | -93.9% |
| Dec 2025 | -246.8% |
| Sep 2025 | -40.1% |
| Jun 2025 | -51.7% |
| Mar 2025 | -58.9% |
| Dec 2024 | -9.2% |
| Sep 2024 | -11.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$143.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VNDA
| FY Dec 2025 | -$110.4M |
| FY Dec 2024 | -$16.2M |
| FY Dec 2023 | $12.4M |
| FY Dec 2022 | $31.3M |
| FY Dec 2021 | $63.7M |
| Jun 2026 | -$31.3M |
| Mar 2026 | -$50.4M |
| Dec 2025 | -$29.5M |
| Sep 2025 | -$31.8M |
| Jun 2025 | -$15.6M |
| Mar 2025 | -$33.6M |
| Dec 2024 | -$2.0M |
| Sep 2024 | -$14.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity VNDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt VNDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-77.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity VNDA
| FY Dec 2025 | -50.9% |
| FY Dec 2024 | -3.5% |
| FY Dec 2023 | +0.5% |
| FY Dec 2022 | +1.2% |
| FY Dec 2021 | +6.9% |
| Jun 2026 | -77.8% |
| Mar 2026 | -60.5% |
| Dec 2025 | -50.9% |
| Sep 2025 | -16.7% |
| Jun 2025 | -13.0% |
| Mar 2025 | -8.4% |
| Dec 2024 | -3.5% |
| Sep 2024 | -3.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-53.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VNDA
| FY Dec 2025 | -38.5% |
| FY Dec 2024 | -2.9% |
| FY Dec 2023 | +0.4% |
| FY Dec 2022 | +1.0% |
| FY Dec 2021 | +5.9% |
| Jun 2026 | -53.0% |
| Mar 2026 | -45.0% |
| Dec 2025 | -38.5% |
| Sep 2025 | -13.5% |
| Jun 2025 | -10.5% |
| Mar 2025 | -6.9% |
| Dec 2024 | -2.9% |
| Sep 2024 | -2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital VNDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-49.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed VNDA
| FY Dec 2025 | -33.6% |
| FY Dec 2024 | -7.3% |
| FY Dec 2023 | -2.5% |
| FY Dec 2022 | +1.2% |
| FY Dec 2021 | +8.5% |
| Jun 2026 | -49.4% |
| Mar 2026 | -38.8% |
| Dec 2025 | -33.6% |
| Sep 2025 | -23.3% |
| Jun 2025 | -19.0% |
| Mar 2025 | -13.3% |
| Dec 2024 | -7.3% |
| Sep 2024 | -6.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing VNDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 105.50x |
| FY Dec 2022 | 61.58x |
| FY Dec 2021 | 27.05x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value VNDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-59.3%
TTM free cash flow over market value at close 2026-10-27
FCF yield VNDA
| FY Dec 2025 | -21.2% |
| FY Dec 2024 | -5.8% |
| FY Dec 2023 | +5.1% |
| FY Dec 2022 | +7.5% |
| FY Dec 2021 | +7.3% |
| Jun 2026 | -38.9% |
| Mar 2026 | -31.2% |
| Dec 2025 | -21.2% |
| Sep 2025 | -28.1% |
| Jun 2025 | -23.7% |
| Mar 2025 | -21.4% |
| Dec 2024 | -5.8% |
| Sep 2024 | -6.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing VNDA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.78x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M |
| Operating income | -$151.2M | -$40.7M | -$14.0M | $6.3M |
| Net income | -$220.5M | -$18.9M | $2.5M | $6.3M |
| EPS (diluted) | -3.74 | -0.33 | 0.04 | 0.11 |
| Operating cash flow | -$109.4M | -$15.8M | $12.8M | $32.0M |
| Cash | $84.9M | $102.3M | $135.8M | $135.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
VNDA Stock Sonar score 4/7 axes
Find similar shapesCompareVNDA ranks highest on institutional and government (66th percentile) and growth (58th), and lowest on risk and compliance (32nd), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
